LYELL IMMUNOPHARMA IN

Cellares and Lyell to Evaluate Automated Manufacturing of Lyell’s CAR T-Cell Therapy on Cellares’ Cell Shuttle Platform

11 Sep 2023 08:00:00 By Nasdaq GlobeNewswire

Lyell Immunopharma to Participate in Upcoming Investor Conferences

31 Aug 2023 16:05:00 By Nasdaq GlobeNewswire

Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2023

08 Aug 2023 16:05:01 By Nasdaq GlobeNewswire

Lyell Immunopharma Appoints Matthew Lang as Chief Business Officer

05 Jul 2023 16:05:00 By Nasdaq GlobeNewswire

Lyell Immunopharma to Participate in the Goldman Sachs Global Healthcare Conference

07 Jun 2023 16:05:00 By Nasdaq GlobeNewswire

Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2023

04 May 2023 16:05:02 By Nasdaq GlobeNewswire

Lyell Immunopharma to Participate in BofA Securities Healthcare Conference

02 May 2023 16:05:00 By Nasdaq GlobeNewswire

Lyell Immunopharma Reports Business Highlights and Financial Results for the Fourth Quarter and Full Year 2022

28 Feb 2023 16:05:00 By Nasdaq GlobeNewswire

Lyell Immunopharma to Participate in 41st Annual J.P. Morgan Healthcare Conference

03 Jan 2023 16:05:00 By Nasdaq GlobeNewswire

Lyell Immunopharma Appoints Lynn Seely, MD as President and Chief Executive Officer

15 Dec 2022 07:00:00 By Nasdaq GlobeNewswire

Lyell Immunopharma to Participate in BofA Securities Biotech Conference

01 Dec 2022 16:05:00 By Nasdaq GlobeNewswire

Lyell Immunopharma to Participate in Barclays Virtual Fireside Chat Series

10 Nov 2022 16:05:01 By Nasdaq GlobeNewswire

Lyell Immunopharma Reports Recent Business Highlights and Third Quarter Financial Results

08 Nov 2022 16:05:01 By Nasdaq GlobeNewswire

Lyell Immunopharma Presents New Data at SITC Highlighting its Growing Pipeline of T – Cell Reprogramming Technologies and Product Candidates Targeting Solid Tumors

07 Nov 2022 08:05:00 By Nasdaq GlobeNewswire

Lyell Immunopharma to Participate in Credit Suisse Healthcare Conference

02 Nov 2022 16:05:01 By Nasdaq GlobeNewswire

Lyell Immunopharma Announces FDA Clearance of its IND for LYL845, a TIL Product Candidate Enhanced with its Novel Epigenetic Reprogramming Technology for Solid Tumors

06 Oct 2022 16:05:00 By Nasdaq GlobeNewswire

Lyell Immunopharma to Present Preclinical Data Highlighting New T-Cell Reprogramming Technologies and its Growing Pipeline at 2022 Society for Immunotherapy of Cancer (SITC) Annual Meeting

05 Oct 2022 08:05:00 By Nasdaq GlobeNewswire

Lyell Immunopharma Announces the Appointment of Rahsaan Thompson as Chief Legal Officer

28 Sep 2022 16:05:00 By Nasdaq GlobeNewswire

Lyell Immunopharma Presents First in Human Trial Design of LYL797 at ESMO 2022

12 Sep 2022 03:00:00 By Nasdaq GlobeNewswire

Lyell Immunopharma to Participate in Morgan Stanley Global Healthcare Conference

30 Aug 2022 16:05:00 By Nasdaq GlobeNewswire